IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needles, and guiding needles/introducers; and IceSense3 system for ablation indications in urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MSense, a multi probe system for the treatment of multiple and larger tumors. The company serves hospitals, interventional radiological centers, ambulatory centers, and private clinics. IceCure Medical Ltd was incorporated in 2006 and is headquartered in Caesarea, Israel.
Часто задаваемые вопросы
В каком секторе работает Icecure Medical (ICCM)?
Icecure Medical относится к сектору Здравоохранение.
Какова текущая цена акций Icecure Medical (ICCM)?
По последним данным, цена акций Icecure Medical составляет 1,03 $, предыдущее закрытие — 1,03 $.
Выплачивает ли Icecure Medical (ICCM) дивиденды?
Нет, Icecure Medical не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у Icecure Medical (ICCM)?
У компании Icecure Medical бета 0.468, что указывает на более низкую волатильность по сравнению с рынком в целом.
